Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study

PURPOSE: Pasireotide (SOM230), a novel multireceptor ligand somatostatin analog (SSA), binds with high affinity to four of the five somatostatin receptor subtypes (sst(1–3, 5)). This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics profiles of pasireotide long-acting...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolin, Edward M., Hu, Ke, Hughes, Gareth, Bouillaud, Emmanuel, Giannone, Vanessa, Resendiz, Karina Hermosillo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3719006/
https://www.ncbi.nlm.nih.gov/pubmed/23765178
http://dx.doi.org/10.1007/s00280-013-2202-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3719006/
https://www.ncbi.nlm.nih.gov/pubmed/23765178
http://dx.doi.org/10.1007/s00280-013-2202-1

Ejemplares similares